Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature

Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature

Summary: The HIV fusion peptide (FP) is a promising vaccine target. FP-directed monoclonal antibodies from vaccinated macaques have been identified that neutralize up to ∼60% of HIV strains; these vaccinations, however, have involved ∼1 year with an extended neutralization-eclipse phase without meas...

Full description

Bibliographic Details
Main Authors: Cheng Cheng, Hongying Duan, Kai Xu, Gwo-Yu Chuang, Angela R. Corrigan, Hui Geng, Sijy O’Dell, Li Ou, Michael Chambers, Anita Changela, Xuejun Chen, Kathryn E. Foulds, Edward K. Sarfo, Alexander J. Jafari, Kurt R. Hill, Rui Kong, Kevin Liu, John P. Todd, Yaroslav Tsybovsky, Raffaello Verardi, Shuishu Wang, Yiran Wang, Winston Wu, Tongqing Zhou, Frank J. Arnold, Nicole A. Doria-Rose, Richard A. Koup, Adrian B. McDermott, Diana G. Scorpio, Michael Worobey, Lawrence Shapiro, John R. Mascola, Peter D. Kwong
Format: Article
Language:English
Published: Elsevier 2020-08-01
Series:Cell Reports
Subjects:
early signature
envelope trimer
fusion peptide
HIV vaccine
immune monitoring
immunization regimen
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124720309669

Internet

http://www.sciencedirect.com/science/article/pii/S2211124720309669

Similar Items